According to CervoMed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.873166. At the end of 2022 the company had a P/E ratio of -0.6614.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.6614 | -47.64% |
2021 | -1.26 | -52.63% |
2020 | -2.67 | 1147.58% |
2019 | -0.2137 | -8.49% |
2018 | -0.2336 | -69.31% |
2017 | -0.7610 | -40.74% |
2016 | -1.28 | -66.74% |
2015 | -3.86 | 8.71% |
2014 | -3.55 | 233.42% |
2013 | -1.07 | -53.78% |
2012 | -2.30 | 29.09% |
2011 | -1.79 | -62.03% |
2010 | -4.70 | -87.68% |
2009 | -38.2 | -5.48% |
2008 | -40.4 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.